Legend Biotech Corporatio... (LEGN)

AI Score

Unlock

37.02

-0.70 (-1.86%)

At close: Mar 21, 2025, 11:22 AM

-1.86% (1D)

Bid	36.78
Market Cap	3.4B
Revenue (ttm)	314.65M
Net Income (ttm)	-88.8M
EPS (ttm)	-0.96
PE Ratio (ttm)	-38.56
Forward PE	-48.09
Analyst	Buy

Ask	37.25
Volume	365,279
Avg. Volume (20D)	1,219,510
Open	37.06
Previous Close	37.72
Day's Range	36.16 - 37.15
52-Week Range	30.17 - 60.87
Beta	0.20

About LEGN

Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery and development of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM), as well as a comparison of the treatment with standard triplet therapy in revlimid-refr...

[Show more]

Industry Biotechnology

Sector Healthcare

IPO Date Jun 5, 2020

Employees 2,600

Stock Exchange NASDAQ

Ticker Symbol LEGN

Website https://www.legendbiotech.com

Full Company Profile

Analyst Forecast

According to 12 analyst ratings, the average rating for LEGN stock is "Buy." The 12-month stock price forecast is $80, which is an increase of 116.10% from the latest price.

Stock Forecasts

Earnings Surprise

Legend Biotech has released their quartely earnings on Mar 11, 2025:

Revenue of $186.52M exceeds estimates by $7.59M, with 134.73% YoY growth.

EPS of -0.15 exceeds estimates by 0.18, with 62.50% YoY growth.

Next Earnings Release

Legend Biotech Corporation is scheduled to release its earnings on May 12, 2025, before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription

Why Price Moved

1 week ago

+9.29%

Legend Biotech Corporation shares are trading high... Unlock content with Pro Subscription

1 month ago

+6.15%

Legend Biotech shares are trading higher. HC Wainwright & Co. reiterated a Buy rating on the stock.

News

1 week ago · seekingalpha.com

Legend Biotech Corporation (LEGN) Q4 2024 Earnings Call Transcript

Legend Biotech Corporation (NASDAQ:LEGN ) Q4 2024 Earnings Conference Call March 11, 2025 8:00 AM ET Company Participants Caroline Paul - Associate Director, IR Ying Huang - CEO Jessie Yeung - Interim...

2 months ago · seekingalpha.com

Top 5 Commercial Biotech Buyout Candidates: Legend Biotech (No. 4)

Legend Biotech is a commercial-stage biotech company specializing in innovative cell therapies, with a strong pipeline and global R&D presence. LEGN's flagship product, CARVYKTI, has received multiple...